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in disease-specific variables, such as motor, cognitive and 
functional performance, structural MRI and serum metabo-
lomic analysis. 12 patients completed the study; reasons for 
withdrawal included problems tolerating study procedures 
(MRI, and venepuncture), depression requiring hospital 
admission and logistical reasons. Three serious adverse 
events were recorded, including hospitalisation for depres-
sion, but none were thought to be drug-related. Changes 
in secondary outcomes were analysed as the annual rate of 
change in the study group. The overall change was com-
parable to changes seen in recent large observational stud-
ies in HD patients, though direct statistical comparisons to 
these studies were not made. Chronic oral administration of 
rilmenidine is feasible and well-tolerated and future, larger, 
placebo-controlled, studies in HD are warranted.
Trial registration: EudraCT number 2009-018119-14.
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Introduction
Huntington’s disease (HD) is a neurodegenerative disorder 
which presents with a combination of movement, psychi-
atric and cognitive deficits (reviewed in Bates et al. [1]). It 
typically progresses with increasing disability to death over 
the course of 15–20 years. There are currently no disease-
modifying treatments available which can alter the progres-
sion of HD [2].
From the very first description, it was recognised that the 
condition is familial, and the underlying genetic mutation, 
an expanded trinucleotide repeat in the Huntingtin gene on 
the short arm of chromosome four, was identified in 1993 
[3]. This has led to a better understanding of the molecular 
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in patients. Consequently, a 2-year open-label study exam-
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was the number of withdrawals and serious adverse events. 
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pathophysiology of the condition, and consequently to rational 
treatment approaches. One example of this has been the recog-
nition that the mutant protein produced by the genetic mutation 
is a substrate for degradation by autophagy [4].
Autophagy describes a process where intracytoplasmic ves-
icles, called autophagosomes, deliver cytoplasmic contents to 
lysosomes for degradation. It is amenable to up-regulation by 
drugs in a variety of cellular, fly, zebrafish and mouse models 
of HD, and this strategy ameliorates signs of the disease in 
these models. The original drug that was shown to do this was 
rapamycin, an inhibitor of the mammalian target of rapamycin 
or mTOR [5]. However, while this drug is approved for human 
use, it has a significant side effect profile including immu-
nosuppression making it an unattractive option for trialling 
in patients with chronic neurodegenerative disorders of the 
CNS. Subsequent drug screens have identified less toxic up-
regulators of autophagy which still retain the ability to rescue 
cells and behaviour in mammalian and other models of HD 
[6]. One such drug is rilmenidine (N-(dicyclopropylmethyl)-
4,5-dihydro-2-oxazolamine), an α2 receptor antagonist and an 
imidazoline  I1 receptor agonist [7]. It has been extensively 
used in the clinic as a centrally acting anti-hypertensive agent 
with no significant side effects compared to placebo at doses 
of 1 mg per day and with an extensive safety record in human 
use including elderly subjects. Thus, this agent is an ideal 
candidate to assess for the feasibility and tolerability of this 
approach in patients with HD.
Investigating whether such treatments can really slow 
disease progression in chronic neurodegenerative disorders, 
such as HD, will require large expensive studies. Indeed, 
longitudinal observational studies of patients with Hunting-
ton’s disease over 2–3 years (for example, COHORT [8] 
and TRACK-HD [9–12]) have highlighted that definitively 
studying the effects of disease-modifying agents on HD 
will require large numbers of patients followed for several 
years. However, before embarking on studies of this type, it 
is important to ascertain that the drug to be trialled is well 
tolerated and the study feasible.
We therefore undertook a first in HD small open-label 
study over a 2-year period looking at the tolerability and 
feasibility of rilmenidine as a possible disease-modifying 
agent. While no account of its effectiveness can be con-
cluded from such a study, it has provided encouraging data 
which can now be used to plan more definitive large-scale, 
multi-centre, double-blind, placebo control trials.
Methods
Trial design and participants
This was a single centre open-label study carried out 
with patients recruited from the regional HD clinic at the 
Cambridge University Hospitals NHS Trust (Addenbrooke’s 
Hospital), UK. Written informed consent was obtained from 
all participants.
Inclusion criteria
1. A confirmed diagnosis of Huntington’s disease on the 
basis of qualifying clinical signs and symptoms, spe-
cifically a Unified Huntington’s Disease Rating Scale 
1999 (UHDRS) total motor score of at least 5 [9], and 
confirmation of a CAG repeat of > 36 in exon 1 of the 
htt gene.
2. HD stage 2–3 as defined using a UHDRS total func-
tional capacity (TFC) score of greater than 4 [13].
3. Ambulant and able to self-care independently.
4. Aged between 18 and 70.
5. English speaking and able to give written, informed con-
sent.
Exclusion criteria
 1. An ongoing clinically significant and unstable gen-
eral medical condition [including but not limited 
to; asthma, chronic obstructive pulmonary disease 
(COPD), ongoing ischaemic heart disease problems 
(IHD), congestive cardiac failure (CCF), left bundle 
branch block (LBBB) or a cerebrovascular accident 
(CVA)] confirmed via past medical history or baseline 
medical or physical examination and investigations.
 2. Prescribed anti-hypertensive medication or any drug 
known to be contraindicated or to have an adverse 
interaction with rilmenidine (viz. a monoamine oxi-
dase inhibitor).
 3. Known hypersensitivity to rilmenidine.
 4. Ongoing significant mental illness determined by evi-
dence, or a history, of a psychotic or affective (depres-
sion or mania) episode in the 6 months prior to base-
line Interview as assessed using the Diagnostic and 
Statistical Manual of Mental Disorders criteria (Fourth 
Edition with Text Revision; American Psychiatric 
Association).
 5. Prescribed typical or atypical anti-psychotic medica-
tion when being explicitly used to treat a psychotic 
illness (as opposed to the movement disorder of HD).
 6. Pregnant or breastfeeding female patients, including 
those planning to conceive during the period of the 
trial. Women of childbearing age who were neither 
pregnant nor planning to conceive during the period 
of the study were deemed eligible provided they used 
two forms of contraception, at least one of which had 
to be a barrier method.
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 7. Substance (alcohol or illegal/prescription drug) misuse 
in the 6 months prior to the baseline assessment.
 8. Known co-morbid major neurological disorder (includ-
ing Parkinson’s disease or an established dementia), 
HIV/AIDS or hepatitis (HBV or HCV).
 9. Previous neurosurgery to the brain.
 10. Marked clinically adverse abnormalities on laboratory 
investigations including creatinine clearance < 15 mg/
min or creatinine serum level > 177 Umol/l.
Interventions and outcomes
All patients were given 1  mg rilmenidine daily for 
6 months and then 2 mg daily for the next 18 months 
of the study. Following screening, patients were seen 
for a baseline assessment and then reviewed at months 
1, 3, 6, 9, 12, 18, 24 and 27 (i.e. 3 months after stop-
ping the rilmenidine). Serious adverse events (SAEs) 
and withdrawals (all primary endpoints) were recorded 
along with non-serious adverse events, height, weight, 
vital signs, routine haematology and biochemistry blood 
measures and ECG occurred as per the schedule of events 
(Table 1).
Specific measures of the progression of their HD included 
UHDRS total motor score, functional and independence 
scales [13] as well as their performance on the trail mak-
ing test, Mini Mental State Examination (MMSE) [14] and 
verbal fluency tasks (as assessed by the controlled oral word 
association test, COWAT).
Other cognitive tests from the Cambridge Automated 
Neuropsychological Test Automated Battery (CANTAB) 
[15] were also used and included the mean time taken 
(latency) and total number of correctly solved problems on 
the One Touch Stockings of Cambridge, and the total num-
ber of errors made prior to and at the extra-dimensional shift 
stage of the CANTAB intra-dimensional/extra-dimensional 
set-shifting task (ID/ED) [15]).
The schedule of events is shown in Table 1.
Sample size and statistical methods
The estimate of the required sample size (n = 16) was 
designed to detect SAEs/AEs rather than a significant change 
in secondary endpoints and was based on data gathered from 
our previous studies using metabolomic biomarkers in HD 
patients [16]. The number of serious adverse events and 
dropouts was analysed with an exact binomial test, testing 
whether the rates were greater than an acceptable safety level 
of 5% per year, or 10% over the course of the study. One-
sided p values and 95% CI are reported.
For secondary outcomes, the mean rate of progression 
(slope) was the main parameter of interest. These outcomes 
were analysed with multilevel models allowing for patient-
specific intercepts and slopes. The basic model for the sec-
ondary analyses was
where yij is the outcome for patient i at time j, and αpatient and 
βpatient are the patient-specific intercepts and slopes, respec-
tively. Priors for model parameters were non-informative (or 
yij ∼ Normal(훼patient[i] + 훽patient[i]timeij, 휎휀),
Table 1  Assessment schedule 






Medical history, family history and physical examination X X x X
Weight X X x X
Vital signs (blood pressure and pulse/heart rate) X X x X
Haematology X X x X
Biochemistry X X x X
12-Lead ECG X X x X
Review of adverse events X X x X
Blood sample for metabolomics X x X
Review of concomitant medications X x X
Magnetic resonance imaging (brain) X X
Unified Huntington’s Disease Rating Scale X x X
Mini mental State Examination X x X
Neuropsychiatric Inventory X x x
Trail making test X x X
Verbal fluency X x X
Tower of London (One Touch Stockings of Cambridge) X x X
Extra-dimensional/intra-dimensional shifts X x X
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very mildly informative to aid convergence). For positively 
skewed outcomes, the data were log-transformed and some 
outcomes used a binomial or negative binomial likelihood if 
the data was better modelled as proportions or counts. The 
results are presented as the annual rate of change and the 
confidence intervals are the 95% highest posterior density 
intervals. p values represent the proportion of the poste-
rior density on the opposite side of zero from the estimated 
mean. For example, the UHDRS motor score increased by 
3.5 units annually, and the associated p value of 0.0063 
tells us that 0.63% of the posterior distribution had negative 
values. The data were analysed with the Bayesian software 
“Stan” and the rstan and rethinking R packages [17, 18].
Given the large number of secondary variables and the 
lack of direct hypothesis testing, no statistical adjustment 
has been made for multiple testing.
Imaging
16 patients underwent structural MR imaging at the 
Cambridge Biomedical Campus using a 1.5 T GE Medi-
cal Systems Discovery MR450 scanner. Structural MRI 
scans were collected prior to commencement of treatment 
and at 27 months (i.e. 3 months after treatment ceased) to 
avoid any effects of the medication on brain volumes and 
fluid shifts, given its known anti-hypertensive actions. A 
T1-weighted 3D Bravo fast spoiled gradient echo (SPGR) 
image was acquired with repetition time (TR) = 8156 ms, 
echo time (TE) = 3.18 ms, matrix = 256 × 256, in-plane 
resolution of 1 × 1 mm, 252 slices of 1 mm thickness, inver-
sion time = 900 ms and flip angle = 9°.
Analysis of the MRI data was performed using Freesurfer 
v. 6 (stable-v6-beta-20151015). The region of interest (ROI) 
values was imported into SPSS. A paired t test was used to 
estimate the changes in volume between the two time-points.
Blood sampling and metabolomic analysis
Blood sampling for metabolomic analysis by gas chromatog-
raphy–mass spectrometry was also undertaken using tech-
niques previously described [16]. Metabolomic analysis is a 
technique which provides multivariate quantitative analysis 
of molecular fragments. Measuring the presence of a large 
number of these fragments and their relative abundance 
leads to a molecular profile which can help differentiate 
between disease states and may also be useful as a potential 
biomarker of progression. There is reason to believe that 
metabolism is altered in HD and a number of papers have 
now described metabolomic changes in HD, including from 
our own group [16]. In this study, we performed sequen-
tial longitudinal metabolomic analysis in each patient as an 
exploratory potential biomarker of disease progression.
Results
Eighteen patients were recruited to the study. One dropped 
out before the treatment was started as the patient was 
unable to tolerate MRI scanning. A further individual 
dropped out at the 1-month visit as the patient was unable 
to tolerate venepuncture. This left 16 patients for whom 
there were more than one observation and who formed 
the trial population. One patient withdrew from the study 
after 6 months when they became depressed and required 
psychiatric admission. One further patient dropped out at 
21 months as the patient was no longer able to travel to 
clinic and two after the 24-month visit, one who no longer 
wished to continue in the trial and the other was lost to fol-
low-up. Thus, 12 patients completed the 27-month follow-
up visit. Excessive movement artefacts in the T1 image 
of the follow-up visit of one participant meant that 11 
patients were included in the longitudinal imaging study. 
This is summarised in Fig. 1.
Screened n=18










Completed 24 month follow-up
n=14
Fig. 1  Patient flow through the study
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Recruitment
Recruitment occurred between October 2012 and July 2013. 
The final patient final visit (FPFV) was completed in June 
2015.
Baseline data
Baseline demographic and clinical characteristics are shown 
in Table 2.
Primary outcome measures
Of the 18 patients who were recruited to the study, 6 with-
drew for the reasons given above. The number of with-
drawals was greater than the pre-specified target rate of 
0.1 (p = 0.0002, 6/18 patients = 0.33 dropout rate; 95% CI 
0.16–1.0). However, none of the withdrawals were consid-
ered to be drug-related.
Three serious adverse events (SAEs) were reported: one 
broken wrist from a physical fall, one admission to hospital 
for migraine after the individual withdrew their migraine 
prophylaxis treatment, and one admission for depression fol-
lowing cessation of antidepressants. None were thought to 
be drug-related.
Secondary outcome measures
The secondary outcome measures are summarised in 
Table  3 (secondary outcome measures) and Table  4 
(changes in regional brain volume on MRI). Of the sec-
ondary endpoints, the UHDRS total motor score (+ 3.5, 
95% CI 0.8–6.3, p = 0.009), whole brain volume (− 1.3%, 
p = 0.001) and UHDRS functional capacity (− 0.4, 95% CI 
0.8–0.02, p = 0.020) showed a decline over the study period 
as expected.
In terms of cognitive tests, latency to correct time on the 
CANTAB One Touch Stockings of Cambridge improved 
(− 0.12, 95% CI − 0.23 to − 0.01, p = 0.014), with no sig-
nificant changes in any of the other cognitive tests.
The MRI data revealed a decline in total brain volume 
(excluding ventricles) of − 1.8% per year (p = 0.001), 
although with respect to the basal ganglia, only the left puta-
men showed a significant decrease in size over the course of 
the study. Other secondary endpoints did not significantly 
change over the study.
All other endpoints remained unchanged including the 
metabolomic analysis where no significant differences were 
noted between baseline and the end of study including in 
Table 2  Baseline demographic and clinical characteristics
BMI body mass index, MMSE Mini Mental State Exam, UHDRS Uni-
fied Huntington’s Disease Rating Scale
Sex 11 male 5 female




Verbal fluency 23.2 (6–53)
UHDRS motor 24.5 (7–46)
UHDRS functional capacity 9.62 (5–13)
UHDRS functional assessment 28.2 (25–35)
UHDRS independence 80 (70–100)
Table 3  Secondary outcome 
measures (ordered by 
significance of the p value)
CANTAB One Touch Stockings of Cambridge
ED extra-dimensional shift on the CANTAB intra-dimensional/extra-dimensional set-shifting task, MMSE 
Mini Mental State Examination, UHDRS Unified Huntington’s Disease Rating Scale
Variable Units Change per annum Lower CI Upper CI p value
UHDRS (motor) Score 3.5 0.8 6.3 0.009
OTS-latency to correct Log s − 0.12 − 0.23 − 0.01 0.014
UHDRS (total functional capacity) Score − 0.4 − 0.8 − 0.02 0.020
EDS errors Number − 0.2 − 0.5 0.06 0.050
UHDRS (functional assessment). Score 0.7 − 0.2 1.5 0.063
Trail B Log s 0.13 − 0.06 0.32 0.081
UHDRS independence scale Score − 1.1 − 2.9 0.6 0.100
Weight kg 0.6 − 0.8 2.1 0.190
Verbal Fluency Log value − 0.04 − 0.13 0.06 0.221
MMSE Score 0.1 − 0.3 0.5 0.263
OTS problems solved on first choice Log odds 0.06 − 0.18 0.31 0.300
Systolic blood pressure mmHg − 0.95 − 5.09 3.16 0.318
Trail A Log s 0.01 − 0.11 0.13 0.429
Pre ED errors Log odds 0.05 − 0.70 0.78 0.455
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metabolites that had previously been associated with pro-
gression of HD [16]. These complex multivariate results will 
be reported in a separate paper.
Haematological, biochemical and ECG changes
Of the routine blood samples taken for haematological, 
renal and liver function, no consistent or sustained changes 
were seen. One individual showed a transient rise in cre-
atine kinase which settled by their next visit. Two individu-
als showed mild and temporary derangement of their LFTs 
which, on review by a hepatologist, required no further 
investigation or treatment. All ECGs were reviewed by a 
consultant cardiologist. Two ECGs showed ventricular 
ectopics during the study. Follow-up showed no underlying 
rhythm abnormality and no treatment was required during or 
after the study. Other AEs are summarised in supplementary 
Table 2.
Discussion
This study has shown that it is feasible to undertake a 
trial of rilmenidine in patients with mild or moderate HD 
and that rilmenidine was well tolerated. While this 2-year 
open-label study reported no drug-related serious adverse 
events and withdrawals, it was also not able to ascertain 
whether there was any efficacy of this agent as the trial was 
not designed to test for drug-related changes in secondary 
outcome measures. However, the data do show changes that 
are less than, or equal, to that expected in patients at this 
stage of disease using recent large historical control data [8, 
12]. This observation needs to be viewed cautiously given 
we had no placebo arm in this study and because the large 
cohort studies of HD populations that have been reported 
differ in the way they were designed and analysed. However, 
we did, for example, find a lower rate of generalised brain 
atrophy (− 1.5% per year seen here versus − 2.05% points 
per year) and basal ganglia volume loss (+ 0.8 to 1.0% per 
year seen here versus − 7.46% points per year) than that 
seen in TRACK-HD [12], a smaller decline in MMSE scores 
(+ 0.1 points per year seen here versus − 0.7 points per year) 
[19] and a smaller reduction in the UHDRS total functional 
capacity score (+ 0.4 points per year seen here versus + 0.6 
points per year) than in the COHORT study [20]. In con-
trast, increases in UHDRS total motor scores were similar 
(+ 3.5 points per year versus + 3 points per year) to that seen 
in both the TRACK-HD ([12] and COHORT studies [8]). 
Weight and cognitive tests did not decline significantly over 
the course of the study, though it is impossible to rule out 
the possibility of a learning effect with these cognitive tests.
We also examined metabolomic changes over time, given 
we have previously found differences in patients with HD 
and controls [16]. We found no differences over the course of 
the study. This is the first longitudinal study in HD to inves-
tigate metabolomic analysis as a possible study endpoint.
This study has a number of limitations. First, it is open 
label with a small number of patients. Second, there were 
several dropouts towards the end of the trial, which although 
not drug-related, nevertheless reduced the power to draw 
any conclusions. Third, the study followed patients for only 
2 years but effects on disease modification, in either direc-
tion, may need longer follow-up to become apparent. Finally, 
we were unable to measure target engagement in the CNS 
in terms of whether the rilmenidine truly did up-regulate 
autophagy at the intended site. Until this can be resolved, 
studies of this type can only postulate that any effects are 
mediated via this intracellular pathway.
Table 4  Changes in regional brain volume on MRI (ordered by the 
significance of the p value)
Percent volume change per year for selected regions
p values from one-sample t test
Only one region had a significantly non-normal distribution accord-
ing to Shapiro–Wilk which was right hippocampus (p = 0.04)
Region Percent change p value
Left lateral ventricle 7.2 <0.001
Right lateral ventricle 6.6 <0.001
Brain volume − 1.3 0.001
Brain volume exc. ventricle − 1.8 0.001
Left putamen − 4.4 0.002
Right inferior lateral ventricle 8.1 0.002
Brain stem − 0.9 0.003
Left cerebellum cortex − 0.9 0.003
Pons − 0.8 0.003
Left inferior lateral ventricle 9.6 0.005
Right cerebellum cortex − 1.0 0.009
Total grey matter volume − 1.5 0.016
Cerebral white matter volume − 2.2 0.019
Subcort grey matter volume − 1.2 0.02
Cerebral cortex volume − 1.8 0.038
Midbrain − 0.4 0.174
Right thalamus proper − 1.4 0.195
Right putamen − 2.1 0.282
Left amygdala − 0.7 0.296
Left thalamus proper − 0.9 0.328
Right amygdala − 0.6 0.487
Medulla 0.4 0.549
Right hippocampus − 0.2 0.618
Left caudate 0.8 0.621
Left accumbens area − 1.2 0.75
Right caudate 1.0 0.797
Right accumbens area − 0.4 0.905
Left hippocampus 0.0 0.957
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In summary, this study has shown that rilmenidine 
appears to be relatively safe and well tolerated in clini-
cally manifest Huntington’s disease. Whether it slows 
down disease progression through an effect on autophagy 
is unresolved, but the data from our trial would encour-
age undertaking further studies with this agent in larger, 
randomised, placebo-controlled trials.
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